FDA approves Jazz's Ziihera in frontline gastric cancer

Jazz Pharmaceuticals’ bispecific antibody Ziihera won a label expansion to treat certain patients with gastric cancer. It’s the first time Ziihera will be marketed to newly diagnosed patients, following its 2024 approval for certain patients ...